The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03032107
Recruitment Status : Active, not recruiting
First Posted : January 26, 2017
Last Update Posted : July 26, 2022
Sponsor:
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Sara Tolaney, Dana-Farber Cancer Institute

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : October 29, 2020
Estimated Study Completion Date : January 1, 2025
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 May 17, 2023
 January 31, 2024
2 March 12, 2024
(Canceled on March 13, 2024)
March 13, 2024
 
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):